PATENT CLAIM ANALYSIS

Application Number: 15765040
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-10
Patent Classification: ["514", "280000"]

Abstract:
Trilobine and its natural triple-bridged bisbenzylisoquinoline alkaloidal analogues as DNMT inhibitors for use as a drug for the treatment of cancer and neurological diseases and for cell reprogramming, in particular to prime for chemotherapy or immunotherapy.

Claim (Index 22):
The method according to  claim 21 , wherein the lung cancer is a non-small cell lung cancer; the lymphoma is a B- or T-cell lymphoma or an anaplastic large-cell lymphoma; and the leukemia is an acute myeloid leukemia (AML), a myelodysplastic syndrome (MDS), a chronic myelomonocytic leukemia (CMML) or a chronic myeloid leukemia (CML).

Metadata:
- Claim Count in Document: 35.0
- Percentile: 90.0
- Lexical Diversity: 1.1875
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15765048', '12528020', '15775746', '15508063', '15315326']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7284200142372563
- 35 USC 102 Novelty (BERT): 0.5298076145915595
- Combined Prediction Score: 0.7085587742726867
- Mean Citation Score: 217.78997400000003
- Max Citation Score: 284.20834
- Similarity Product: 162.78357138110874

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test